Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has provided an update.
Hansoh Pharmaceutical Group Company Limited held its Annual General Meeting on June 20, 2025, where all proposed resolutions were passed with significant support. Key decisions included the adoption of the company’s financial statements, approval of a final dividend, re-election of directors, and granting of mandates for share repurchase and issuance. These resolutions reflect the company’s stable financial health and strategic plans for growth, potentially enhancing shareholder value and strengthening its market position.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development, production, and sale of innovative medicines. It operates primarily in the healthcare industry, providing a range of pharmaceutical products that cater to various therapeutic areas.
Average Trading Volume: 13,325,127
Technical Sentiment Signal: Buy
Current Market Cap: HK$167.4B
Learn more about 3692 stock on TipRanks’ Stock Analysis page.